- Home
- WAFU vs GRI Comparison
WAFU vs GRI Comparison
Compare WAFU & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WAFU
- GRI
- Stock Information
- Founded
- WAFU 1999
- GRI 2018
- Country
- WAFU China
- GRI United States
- Employees
- WAFU N/A
- GRI N/A
- Industry
- WAFU Other Consumer Services
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- WAFU Real Estate
- GRI Health Care
- Exchange
- WAFU Nasdaq
- GRI Nasdaq
- Market Cap
- WAFU 7.1M
- GRI 6.1M
- IPO Year
- WAFU 2019
- GRI N/A
- Fundamental
- Price
- WAFU $1.47
- GRI $0.78
- Analyst Decision
- WAFU
- GRI Strong Buy
- Analyst Count
- WAFU 0
- GRI 2
- Target Price
- WAFU N/A
- GRI $11.50
- AVG Volume (30 Days)
- WAFU 21.8K
- GRI 377.5K
- Earning Date
- WAFU 01-01-0001
- GRI 11-14-2024
- Dividend Yield
- WAFU N/A
- GRI N/A
- EPS Growth
- WAFU N/A
- GRI N/A
- EPS
- WAFU N/A
- GRI N/A
- Revenue
- WAFU $7,223,220.00
- GRI N/A
- Revenue This Year
- WAFU N/A
- GRI N/A
- Revenue Next Year
- WAFU N/A
- GRI N/A
- P/E Ratio
- WAFU N/A
- GRI N/A
- Revenue Growth
- WAFU N/A
- GRI N/A
- 52 Week Low
- WAFU $1.46
- GRI $0.30
- 52 Week High
- WAFU $2.85
- GRI $65.00
- Technical
- Relative Strength Index (RSI)
- WAFU 33.27
- GRI 49.02
- Support Level
- WAFU $1.46
- GRI $0.75
- Resistance Level
- WAFU $1.59
- GRI $1.00
- Average True Range (ATR)
- WAFU 0.10
- GRI 0.09
- MACD
- WAFU -0.01
- GRI -0.00
- Stochastic Oscillator
- WAFU 2.86
- GRI 38.93
About WAFU Wah Fu Education Group Limited
Wah Fu Education Group Ltd is involved in providing online exam preparation services and related technology solutions and also produces online training course materials in China. It develops online educational materials that are offered through the cloud and that can be used for a wide range of purposes, such as standard examination preparation, professional training, and interactive programs for educational purposes other than exam preparation. Its segments are Online Education Services, and Technological Development and Operation Service. The company generates maximum revenue from the Online Education Services segment.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.